Britain’s Hikma Pharmaceuticals reported a 9% rise in half-year core-operating profit and maintained its annual outlook on Thursday, supported by the generic drugmaker’s turnaround efforts to expand its product base and streamline manufacturing.
US Tariffs
Potential US tariffs on generic drug imports are aimed at boosting domestic manufacturing. Hikma said it was well positioned to support efforts to strengthen its U.S. supply chain, noting that the majority of the medicines it sold in the country were manufactured in Ohio and New Jersey.
Original reporting: Appleton, WI News Feed (HLL/CB) — read the source article.
